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LINICAL INVESTIGATION Normal Tissues
PLASMA CITRULLINE CONCENTRATION: A SURROGATE END POINT FOR
RADIATION-INDUCED MUCOSAL ATROPHY OF THE SMALL BOWEL.
A FEASIBILITY STUDY IN 23 PATIENTS
LUDY C. H. W. LUTGENS, M.D.,* NICOLAAS DEUTZ, M.D., PH.D.,† MARLIES GRANZIER-PEETERS,*
REGINA BEETS-TAN, M.D., PH.D.,‡ DIRK DE RUYSSCHER, M.D., PH.D.,* JOHN GUEULETTE, PH.D.,§
JACK CLEUTJENS, PH.D., MARTIJN BERGER, PH.D.,¶ BRADLY WOUTERS, PH.D.,*
MAARTEN VON MEYENFELDT, M.D., PH.D.,† AND PHILIPPE LAMBIN , M.D., PH.D.*
*Departments of Radiation Oncology (MAASTRO),†Surgery,‡Radiology,Pathology, University Hospital Maastricht, and
¶Methodology and Statistics, Maastricht University, Maastricht, The Netherlands;§Unité de Radiobiologie et Unite´ de
Radiotherapie, Universite´ Catholique de Louvain, Bruxelles, Belgium
Purpose: Plasma citrulline, a nitrogen end product of glutamine metabolism in small-bowel enterocytes, was
suggested as a marker of radiation-induced small-bowel epithelial cell loss in mice after single-dose whole-body
irradiation. Our objective was to evaluate the feasibility of citrulline as a marker for radiation-induced
small-intestinal mucosal atrophy in patients during and after abdominal fractionated radiotherapy.
Methods and Materials: Twenty-three patients were studied weekly during treatment and at intervals of 2 weeks
and 3 and 6 months after treatment by postabsorptive plasma citrulline concentration and clinical toxicity
grading. The interrelationship between these variables and the correlation with small-bowel dose and volume
parameters were investigated.
Results: During fractionated radiotherapy, citrulline concentration significantly decreased as a function of the
radiation dose (p < 0.001) and the volume of small bowel treated (p  0.001). The plasma citrulline concentration
correlated with clinical toxicity during the last 3 weeks of treatment. As a whole, citrulline concentration
correlated better with radiation dose and volume parameters than clinical toxicity grading.
Conclusions: In patients treated with fractionated radiation therapy for abdominal or pelvic cancer sites, plasma
citrulline concentration may be a simple objective marker for monitoring epithelial cell loss, a major event in
acute radiation-induced small-bowel toxicity. © 2004 Elsevier Inc.






































hen treating abdominal or pelvic cancers with radiot
py, either alone or combined with chemotherapy, the s
owel (SB) is the organ most frequently encountere
ose-limiting normal tissue, with regard to both acute
ate treatment-related morbidity. A wide diversity of fu
ional disorders have been observed after ionizing radia
uch as motility dysfunction(1, 2), changes in transepith
ial transport processes(3, 4), or the absorption of variou
utrients, such as carbohydrates, amino acids, protein
amins, and bile acid(5–10). Acute radiation-induced sma
owel toxicity may necessitate treatment interruption
stablished detrimental factor for treatment outcome(11).
fter radiation doses of 45–50 Gy, typically delivered d
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This project was awarded with an ESPEN fellowship at thend
ongress of the European Society of Parenteral and Entera275ng 5 weeks in 25 fractions, actuarial 5-year rates of se
tromal small-bowel injury, such as fistulas and strictu
re usually less than 5%(12). In contrast, persisting fun
ional changes causing chronic diarrhea, malabsorption
ther symptoms associated with epithelial small-bo
amage have been reported in 40–50% of patient(5,
2–15). Both radiation dose and irradiated small-bo
olume (SBV) have been demonstrated as determinan
adiation-induced small-bowel toxicity(12, 16, 17).
Several functional changes have been correlated wi
mpaired absorptive capacity due to radiation-induced
helial cell loss(9, 18–20). At present, no simple biolog
arker is available that is sensitive and specific for ra
ion-induced small-bowel mucosal atrophy. Plasma ci
ine has been suggested as a marker for functional s
rition held in Madrid, Spain, 2000.
cknowledgments—The authors gratefully thank Mrs. G. ten Ha
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276 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 1, 2004owel enterocyte mass (21–26). Citrulline, a nitrogen end
roduct of small-bowel enterocyte glutamine metabolism,
ccounts for almost 30% of metabolized glutamine nitrogen
n the rat small intestine (27). The small-intestinal entero-
yte contains specific mitochondrial enzymes involved in
itrulline production but lacks the cytosolic enzymes nec-
ssary for its conversion to arginine (28–30). This unique
nzymatic profile (25) and the fact that citrulline is not
etabolized by the liver (31) account for the fact that the
mall bowel is the principal source of circulating citrulline.
onsequently, the plasma citrulline concentration is highly
ependent upon the intestinal cell mass (28).
We have validated the use of citrullinemia as an assay for
adiation-induced small-bowel epithelial cell loss in mice
fter exposure to a single homogeneous dose of whole-body
rradiation (26). The aim of the present study was to confirm
ur preclinical results in patients exposed to a fractionated
nhomogeneous dose delivered to the small bowel during
bdominal and/or pelvic irradiation. For this purpose, the
ostabsorptive plasma citrulline concentration has been
easured as a marker for radiation-induced small-bowel
ucosal atrophy immediately preceding treatment and
eekly during treatment. In addition, citrullinemia has been
easured at intervals of 2 weeks and 3 and 6 months after
ompletion of radiotherapy to assess subacute radiation
ffects. Our hypothesis, based on our preclinical data (26),
Table 1. Tr
Patient Malignancy Radiotherapy indicat
9 Bladder† Vaginal and pelvic sidewall
2 Cervix FIGO IB
4 Cervix FIGO IIB, bulky
6 Cervix†‡ FIGO IB2. pNO
10 Cervix†‡ FIGO IB2. pN
13 Cervix†‡ FIGO IVA, bulky, pN0
7 Kidney Retroperitoneal recurrence
3 Uterus Vaginal vault recurrence
12 Uterus Sarcoma FIGO Stage IC. Ad
16 Uterus Carcinoma FIGO Stage IC A
11 Ovary Chemotherapy resistant recu
17 Ovary Chemotherapy resistant recu
8 Prostate pT3. Postoperative
14 Prostate pT3. Postoperative
19 Prostate pT3. Postoperative
20 Prostate Pelvic sidewall recurrence
5 Rectum Pelvic recurrence. Preoperat
21 Rectum Pelvic recurrence. Preoperat
1 Testis Seminoma Stage I. Adjuvan
15 Testis Seminoma Stage I. Adjuvan
18 Testis Seminoma Stage I. Adjuvan
22 Testis Seminoma Stage IIA. Adjuv
23 Vulva Carcinoma. Groin recurrenc
Abbreviations: BCT  brachytherapy; PAO  para-aortic lymph
M  safety margin (typically 2 cm in all directions); WAR  w
* Dose per fraction – Total tumor dose.
† Treatment combined with pelvic hyperthermia once weekly d
‡ Retroperitoneal lymph node dissection.
§ Prostate: preoperative prostate bed including seminal vesicless that changes in citrullinemia are correlated with small-
owel dosimetric and volumetric parameters and with clin-




This study, carried out between November 2001 and
ovember 2002, included 23 successive patients receiving
bdominal and/or pelvic irradiation (RT) at the Maastricht
adiation Oncology Clinic. Patients treated with concomi-
ant chemotherapy or an impaired renal function (Glomer-
lar Filtration Rate according to Cockroft formula 60
L/min) assessed less than 4 weeks before the start of
reatment were excluded. The median age of 9 male and 14
emale patients was 63.1 years (range, 28.3–72.6 years).
he primary tumor site, the indications for radiotherapy,
nd the anatomic treatment sites are summarized in Table 1.
tudied variables
In all patients the assessment of clinical toxicity and the
cquisition of blood samples for plasma citrulline measure-




field border) Treatment schedule*






Recurrence  SM 3–39
Pelvis (L5–S1) 2–70
t Pelvis (L5–S1) 1.8–45
nt Pelvis (L5–S1) 2–46
WAR 0.8–30.4
WAR 0.8–30.4
Prostate§  SM 2–60
Prostate  SM 2–60
Prostate  SM 2–68






























































277Citrulline level in response to fractionated pelvic or abdominal irradiation ● L. LUTGENS et al.linical parameters
Each patient was seen by the responsible physician on a
eekly basis during RT and at 2 weeks and at 3 and 6
onths after completion of RT to assess, where appropriate,
reatment-related morbidity and tumor response. At each
isit, clinical symptoms attributable to SB radiation damage
ere recorded using the Radiation Therapy Oncology
roup (RTOG) scoring criteria for acute radiation morbid-
ty of the lower gastrointestinal tract (32) (Table 2). In
ontravention of the rules for this scoring system, we also
pplied the score at 6 months after RT. For statistical
nalysis, the RTOG scores per time point were used and the
Table 2. Lower Gastrointestinal Radiation Therapy Oncology
Group acute radiation morbidity scoring criteria
0 No change.
1 Increased frequency or change in quality of bowel habits
not requiring medication.
2 Diarrhea requiring parasympatholytic drugs/abdominal pain
requiring analgesics.
3 Diarrhea requiring parenteral support/abdominal distention
(flat plate radiograph demonstrates distended bowel
loops).
4 Acute or subacute obstruction, fistula, or perforation. GI
bleeding requiring transfusion; abdominal pain requiring
tube decompression or bowel diversion.
5 Any toxicity that causes death.
Fig. 1. Assessment of dose and volume parameters usin
treatment planning software. Transverse, coronal, and sa
light blue contour represents the small-bowel contour. T
wash with the red area representing a dose 50% of the
the irradiation fields. The upper right panel shows the c
Cervix carcinoma. External radiation treatment delivered
and lower para-aortic lymph nodes. Upper level L2–L3,
in 41⁄2 weeks. Mean SB dose 31 Gy. SBV50%  74%.ercentage of the total RT treatment time that a patient was
ree of symptoms ( % zero score).
Patients were classified according to additional treatment
odalities, such as hyperthermia, and the mode of surgery
erformed (i.e., extraperitoneal surgery [I] or i.p. surgery
mmediately preceding RT [II], i.p. surgery more than 6
onths before RT [III], or no abdominal surgery [IV]). In
ddition, patient characteristics such as age, gender, smok-
ng status, length, and body mass index were recorded.
reatment planning
A planning CT scan was performed in supine treatment
osition with full bladder instruction. Patients were in-
tructed to drink 500 mL oral SB contrast solution 30 min
efore the scan. The entire abdomen was imaged in 22
atients. In Patient 5, the volume scanned was limited
ccording to the length of the treatment fields. Adjacent
0-mm-thick transverse images were collected and trans-
erred to a Focus treatment-planning station (C.M.S.). The
arge bowel was defined first on each transverse image. The
B was then defined as both opacified and unopacified
ndividual bowel loops other than large bowel. The small-
owel outer contour was delineated on each transverse
mage, enabling calculation of the total small-bowel volume
Fig. 1). All contouring was done by one of the authors
M.G.) and double checked by two others (R.B., L.L.)
mputed tomography scan in treatment position and 3D
plane reconstructed slices are shown, respectively. The
tive dose distribution is presented by means of a color
ribed tumor dose, i.e., the tissue located actually within
nding small-bowel dose–volume histogram. Patient 4:
ns of 4-field box technique to the primary tumor, pelvic,











































































































278 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 1, 2004ithout knowledge of the results of citrulline measurements
r dose–volume histograms (DVH). This CT-based 3-di-
ensional dose–volume analysis and treatment planning
llowed performance of a quantitative DVH analysis for
ach patient. The total RT plan was used in the DVH
alculation, i.e., both the dose delivered with the primary
T fields and the boost RT fields, respectively. The value of
small-bowel DVH is limited, because of variations in
uminal content and small-bowel motility. However, this
ethod seems appropriate for estimating the proportion of
unctional small bowel receiving a specified radiation dose
17, 33).
For all patients, the small-bowel volume receiving a dose
etween 5 and 55 Gy, recorded at 5-Gy intervals, and the
BV receiving at least 50% of the prescribed radiation dose
SBV50%) were calculated. For statistical analysis, volu-
etric parameters were expressed as the percentage of the
otal SBV. Thus the SBV30 is the fraction of the total
mount of small bowel receiving a dose of at least 30 Gy.
osimetric parameters used for analysis were the cumula-
ive mean dose delivered to the entire SB during successive
reatment weeks and the total mean dose delivered to the
B. Volumetric and dosimetric parameters were correlated
ith the RTOG toxicity score for acute SB radiation-related
orbidity and with the plasma citrulline concentration at
orresponding time points.
adiation treatment
All patients were treated with megavoltage equipment
10-MV linear accelerator). Standard SB exclusion tech-
iques, such as multiple-field techniques, where appropri-
te, and individual lead shielding, were used for treatment
lanning. The International Commission on Radiation Units
nd Measurement (34) reference point was chosen at the
socenter and used for dose prescription. Tumor doses pre-
cribed to the International Commission on Radiation Units
nd Measurement reference point ranged between 25.2 and
0 Gy and are listed in Table 1. RT was delivered daily
sing 1.8–2 Gy per fraction, 5 times per week. Patient 7 was
reated with 3 Gy per fraction, 4 times per week. Two
atients (Patients 11 and 17) were treated with hyperfrac-
ionated whole-abdominal radiation delivering 0.8 Gy per
raction twice daily, 5 days per week. RT treatment time
anged between 3 and 6 weeks. In 5 patients treated for
ervix carcinoma, RT was combined with two high-dose-
ate brachytherapy applications prescribing a dose of 8.5 Gy
o Manchester point A. Brachytherapy was delivered on
onday with an interval of 1 week. The first of two appli-
ations was delivered during the last week of RT or during
he first week after RT, except for Patient 2, who received 2
igh-dose-rate applications during the second and fourth
eek of RT. On days when intracavitary brachytherapy was
pplied, no RT was delivered. In 4 patients, RT was com-
ined with pelvic hyperthermia once weekly (up to a total of
treatments).lasma citrulline
Postabsorptive plasma citrulline concentration was as-
essed on Tuesdays 15 min before irradiation. Subjects were
ampled after an overnight fast and instructed to lie down
or 15 min in a hospital bed, avoiding any physical exertion.
n Tuesdays, irradiation was scheduled between 8:30 and
0:00 am. An antecubital vein was used for sampling 1.5
L blood, which was collected in a heparinized cup and
tored on ice. Plasma was then obtained by whole blood
entrifugation at 10,000  g at 4°C for 10 min. For deter-
ination of amino acids, 250 L plasma was deproteinized
y adding it to 22 mg dry 5-sulfosalicylic acid. Then it was
ortexed, frozen in liquid nitrogen, and stored at 80°C
ntil further processing. Plasma citrulline concentration
mol/L) was measured by using high-performance liquid
hromatography (35). Baseline citrulline level was assessed
t Day 0. Subsequently, citrullinemia was measured weekly
uring RT and at intervals of 2 weeks and 3 and 6 months
fter RT.
tatistical analysis
SPSS for Windows software (Release 11.0) was used for
tatistical analysis. All results are expressed as mean 
EM. Citrulline levels measured at different time points
ere compared using a paired-samples t test. For testing
orrelations between citrulline level and dose–volume and
linical parameters, Pearson correlation and one-way anal-
sis of variance (ANOVA) were used, where appropriate.
ne-way ANOVA was used to test a dose and volume
elationship for serum citrulline and clinical toxicity, re-
pectively. For these tests, threshold levels for the mean SB
ere arbitrarily chosen at 1, 10, and 20 Gy, respectively.
he choice of threshold levels for citrulline was based on a
ecently published correlation between citrulline level and
he extent and severity of epithelial cell loss in patients with
eliac and nonceliac disease (22), i.e., 10, 20, and 30
mol/L, respectively. A p value 0.05 was considered
tatistically significant.
RESULTS
linical and dose–volume histogram parameters
Small-bowel dose–volume histogram parameters are
ummarized in Table 3. The mean total SBV in 22 patients
as 1304 mL (range, 482–2117 mL). Body length was the
nly patient characteristic that was associated with the total
BV (p  0.056). None of the dosimetric or volumetric
arameters listed in Table 3 were associated with patient
haracteristics or with the type of surgery before RT (data
ot shown).
itrulline concentration
All 23 patients completed RT as planned. Citrulline con-
entration and toxicity grading were assessed weekly, ex-
ept for the first treatment week in 2 patients. At 2 weeks





















































279Citrulline level in response to fractionated pelvic or abdominal irradiation ● L. LUTGENS et al.The average baseline citrulline concentration in 23 pa-
ients was 30.9 mol/L (range, 19.1–52.9 mol/L). During
reatment, a significant decline in citrulline concentration
Table 3. Small-bowel dose–volume histogram parameters of all
23 patients*
DVH parameter Mean Range SEM
ean SB dose (Gy) 11.2 0–32.2 2.0
inimum SB dose (Gy) 1.1 0–20.5 0.9
aximum SB dose (Gy) 35.4 0–59.7 3.9
ean SB dose 2nd RT wk
(Gy)
5.0 0–17.0 0.9
otal SBV (ml) 1304 482–2117 96
BV50% (%) 29 0–100 6.2
BV5 (%) 37 0–100 6.5
BV10 (%) 34 0–100 6.4
BV15 (%) 31 0–100 6.3
BV20 (%) 30 0–100 6.2
BV25 (%) 24 0–94 5.7
BV30 (%) 15 0–71 4.2
BV35 (%) 9 0–45 3.0
BV40 (%) 7 0–39 2.3
BV45 (%) 4 0–31 1.6
BV50 (%) 1 0–5 0.3
BV55 (%) 0 0–3 0
Abbreviations: SB  small bowel; SBV  small-bowel volume;
VH  dose–volume histogram; RT  radiotherapy SEM 
tandard error of the mean; SBV50%  the percentage of total
BV receiving at least 50% of the dose prescribed to the ICRU
eference point; SBV5  the percentage of total SBV receiving a
ose of at least 5 Gy.
* Total SBV data available in 22 patients.
Fig. 2. Temporal pattern of plasma citrulline concentratio
toxicity grading relative to radiation treatment. Values fo
The dashed line represents the percentage of patients wi
of patients with RTOG score 2. Abbreviations: BL  ba
2 weeks, 3 and 6 months postradiation. Statistics: 2-sideas observed at the second (p  0.008), third (p  0.003),
nd fourth (p  0.014) treatment week, respectively (Fig.
). The maximum decline was observed during the third
eek of treatment (23.6  2.4 mol/L).
Seventeen of 23 patients displayed a fall in citrulline
oncentration during RT (mean decrease 43%, range: 14%–
6%, p  0.005), whereas 5 patients (Patients 1, 6, 13, 14,
nd 19) displayed a rise in citrulline concentration (mean
ncrease 38%, range, 19%–64%, p  0.003). The baseline
itrulline concentration was lower in patients displaying an
ncrease of citrulline concentration during treatment as com-
ared to patients with decreasing citrulline concentration
25.2  1.3 mol/L and 32.5  2.5 mol/L, respectively),
lthough this was not statistically significant (p  0.16). In
ne patient, the citrulline concentration was unchanged
hroughout RT. None of the patient characteristics or dose–
olume histogram parameters were associated with the cit-
ulline pattern, i.e., either a fall or rise in citrulline concen-
ration.
itrulline: Dose–response relationship
The overall change in citrulline concentration during RT
ignificantly correlated with the total mean SB dose (Pear-
on r  0.72, p  0.001). Citrulline concentration, cate-
orized according to threshold values predictive for the
everity and extent of villous atrophy (22), i.e. (1) 10
mol/L, (2) 10–20 mol/L, (3) 20–30 mol/L, and (4)
30 mol/L, respectively—were associated with different
ean SB doses: 31.6  0.6 Gy, 13.1  2.4 Gy, 9.6  2.5
y, and 2.7  1.7 Gy for citrulline category 1, 2, 3, and 4,
ol/L) and Radiation Therapy Oncology Group (RTOG)
a citrulline level (dashed bar) represent mean  SEM.
G score zero; the drawn line represents the percentage
w1–6  radiation treatment Week 1–6; 2w, 3m, 6m 










































280 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 1, 2004espectively (p  0.001, Fig. 3). A similar significant cor-
elation was found during RT between the citrulline con-
entration and the cumulative mean SB dose: p  0.001, p
0.001, p  0.001, and p  0.004 for RT Week 2, 3, 4, and
, respectively. No correlation was observed at the other
ime points during and after RT. To further explore a
ose–response relationship, threshold levels for the mean
B dose of 1, 10, and 20 Gy were used and yielded similar
esults (Fig. 4).
itrulline: Volume effect
The overall change in citrulline concentration during RT
mol/L) significantly correlated with successive SBV dose
evels between 5 Gy and 35 Gy at 5-Gy intervals. The
olume effect was further analyzed using citrulline thresh-
ld levels of 10, 20, and 30 mol/L, respectively. A signif-
cant volume effect was observed for the SBV dose levels
etween 5 Gy and 35 Gy (Fig. 5). No volume effect was
ound for the 2-week or 3-month and 6-month time points.
adiation-induced small-bowel toxicity (RTOG score)
During RT, temporal changes in radiation-induced SB
oxicity were observed (Fig. 2). The maximum acute SB
oxicity score was 2 during the total observation time in 23
atients. Weekly assessed toxicity was correlated with the
orresponding cumulative mean SB radiation dose. In ad-
ition, the fraction of total treatment time that a patient was
ree from symptoms (% zero score) was correlated with the
otal mean SB dose. For the fourth and fifth treatment week,
tion at successive time points during radiotherapy. The
h dose point is correlated with the plasma citrulline
an small-bowel doses are categorized according to 4
0 Gy, respectively. For comparison of the mean plasma
ategories, the one-way analysis of variance test is used.
n week 2–5. overall  the maximum change in plasmaig. 3. Dose–effect relationship for plasma citrulline concentration
ategorized according to threshold values of 10, 20, and 30
mol/L, yielding 4 groups, i.e., (1) 10 mol/L, (2) 10–20
mol/L, (3) 20–30 mol/L, and (4) 30 mol/L, respectively.
or comparison of the mean small-bowel dose (Gy) between the
espective citrulline categories, the one-way analysis of variance
ANOVA) test with Tukey’s post-hoc testing is used. Data repre-
ent mean  SEM. One-way ANOVA: p  0.001. Tukey’s post-
oc testing: level 1 vs. level 2, level 3, and level 4: p  0.005, p
0.002, and p  0.001, respectively. Level 2 vs. level 3 and 4: p
nonsignificant and p  0.020, respectively. Level 3 vs. level 4:Fig. 4. Dose–effect relationship for plasma citrulline concentra
cumulative mean dose delivered to the small bowel at eac
concentration (mol/L) at the corresponding time point. Me
threshold levels, i.e., 0–1 Gy, 1–10 Gy, 10–20 Gy, and 2
citrulline concentration between the respective threshold dose c
Data represent mean  SEM. Abbreviation: wk 2–5  radiatio






















































281Citrulline level in response to fractionated pelvic or abdominal irradiation ● L. LUTGENS et al.he cumulative mean radiation dose significantly correlated
ith clinical toxicity (Pearson r  0.50 and 0.69; p  0.033
nd p  0.040, respectively). No correlation between tox-
city and RT dose was found at any other time point during
r after RT. The % zero score significantly correlated with
he total mean SB dose (p  0.017). No dose–effect rela-
ionship was observed using the maximum scored toxicity
s parameter (i.e., RTOG score 2).
Weekly assessed toxicity correlated significantly with
uccessive SBV dose levels of 5–30 Gy and 5–35 Gy during
he fourth and fifth treatment week, respectively. No volume
ffect was found at earlier time points during RT or at later
ime points after treatment, respectively. The % zero score
lso correlated significantly with successive SBV dose lev-
ls between 5 and 30 Gy.
orrelation of clinical symptoms with citrulline
oncentration
Citrulline concentration was significantly correlated with
linical toxicity during the fourth and sixth treatment week
Pearson r  0.62 and 0.86; p  0.007 and p  0.027,
espectively), whereas a borderline significant correlation
as found at the fifth treatment week (p  0.060) (Fig. 6).
o such relationship was observed during the first 3 weeks
r after treatment. The weekly assessed % zero score sig-
ificantly correlated with the citrulline concentration during
reatment (Spearman’s rho 0.93). Similarly, the total % zero
core during treatment significantly correlated with the
verall change in plasma citrulline concentration (p 
.002). The % zero score correlated with the four groups of
Fig. 5. Volume–effect for serum citrulline concentration
dose levels at 5-Gy intervals. Citrulline is categorized in
10–20 mol/L, (3) 20–30 mol/L, and (4) 30 mol/
mean (SEM). Abbreviation: SBV5  the percentage of t
analysis, the one-way analysis of variance (ANOVA) te
0.001, 0.001, 0.001, 0.001, 0.001, and 0.045
between each successive group is significant. For SBV20
SBV25–35, the difference in SBV is significant only beitrulline levels categorized according to threshold values of
0, 20, and 30 mol/L, i.e., 38  22%, 41  7%, 53 
3%, and 82  12% for patients with citrulline concentra-
ions 10 mol/L, 10–20 mol/L, 20–30 mol/L, and
30 mol/L, respectively (p  0.036). No such relation-
hip was observed for the maximum scored toxicity (i.e.,
TOG score 2) and citrulline concentration.
The limited number of patients in this study does not
llow a detailed analysis on a threshold level for clinical
ymptoms. For that reason, we used a threshold SBV15 of
50 mL, as used for acute SB toxicity in the recently
ublished article by Baglan et al. (17), although this article
efers specifically to the situation of combined chemother-
py and radiotherapy in patients with rectal cancer. The %
ero score during RT was 83  27% as compared to 44 
4% for patients with an SBV15 150 mL and 150 mL,
espectively (p  0.003). Corresponding serum citrulline
oncentrations were 34.2  13.0 mol/L and 18.4  6.9
mol/L, respectively (p  0.001).
DISCUSSION
The present study demonstrates that plasma citrulline is a
easible marker in clinical practice to monitor radiation-
nduced small-intestinal mucosal atrophy in patients treated
or abdominal and/or pelvic cancers and confirms preclini-
al results in mice after whole-body single-dose irradiation
26). Like surgery (21), celiac and nonceliac disease (22),
nd acute cellular rejection after small-bowel transplanta-
ion (23, 24), ionizing irradiation is an additional event
lume effect is analyzed for small bowel volume (SBV)
oups using 3 threshold levels, i.e., (1) 10 mol/L, (2)
ectively. Data represent means  standard error of the
all-bowel volume receiving at least 5 Gy. For statistical
used with Tukey’s post-hoc testing. p values: 0.001,
BV 5–35, respectively. For SBV 5–15, the difference
fference between category 2 and 3 is not significant. For






















































282 I. J. Radiation Oncology ● Biology ● Physics Volume 60, Number 1, 2004ssociated with reduced small-bowel epithelial cell mass
hat can be monitored by plasma citrulline.
The relationship between plasma citrulline concentration
nd epithelial cell mass has been demonstrated previously in
odents after surgical resection of small bowel (25, 36). In
n experimental study using mice, we suggested plasma
itrulline concentration as marker for small-bowel epithelial
ell mass after a single homogeneous total-body irradiation
26). Recently, several investigators have suggested plasma
itrulline as a specific marker for small-bowel functional
nterocytes in patients (21–24). This is further substantiated
y the present study by adding ionizing irradiation as a
echanism for (temporal) loss of functional enterocytes.
The pathophysiology of clinical symptoms related to
mall-bowel irradiation is complex with mucosal denuda-
ion being one of several events (37–39). In rodents, the
inetics of radiation-induced small-intestinal epithelial
hanges have been well described (40). Radiation damage to
he intestinal crypt cell compartment and consequential
pithelial denudation are strictly dose dependent (40). In
atients, radiation dose, in addition to the volume of irra-
iated small bowel, has been demonstrated as a determinant
or radiation-induced small-bowel toxicity (12, 16, 17).
lasma citrulline concentration decreased as a function of
mall-bowel radiation dose (Figs. 3 and 4) and volume (Fig.
Fig. 6. Correlation between citrulline concentration and t
concentration (mol/L) represent means  standard error
2–6, n.s.  nonsignificant; rtog  Radiation Therapy O). Crenn et al. (22) have recently correlated plasma citrul-
ine concentration with histologically graded villous atrophy
n 42 patients with celiac and 10 patients with nonceliac
illous atrophy disease. These authors identified a threshold
alue of 10 mol/L (25% of the mean normal baseline
alue) to be predictive for severe and extensive villous
trophy and 20 mol/L to be predictive for severe villous
trophy, whatever the extent. Based on these data, we used
he same threshold levels for plasma citrulline to analyze
adiation-induced effects (Figs. 3 and 5). The citrulline
ategories corresponded with different mean small-bowel
oses (Fig. 3) and volumes treated (Fig. 5). Up to a mean
mall-bowel dose of 15 Gy, these threshold levels were
ignificantly associated with the volume of small bowel
reated. For higher dose levels, the 10 mol/L threshold
emains a discriminating factor for the volume of small
owel treated.
Radiation-induced small-bowel toxicity is associated
ith the radiation dose and the volume of small bowel
reated (12, 16, 17). We found a significant dose and volume
ffect for radiation-induced toxicity during the fourth and
fth treatment week. In contrast to other authors (12, 16),
e did not find such a relationship for late sequelae, i.e., at
months. However, the limited number of patients and
score during radiotherapy treatment. Data for citrulline
















































































































283Citrulline level in response to fractionated pelvic or abdominal irradiation ● L. LUTGENS et al.ollow-up, respectively, do not permit conclusions on this
ssue.
Plasma citrulline and the RTOG toxicity score were used
s end points for radiation-induced small-bowel toxicity in
his study. A radiation dose and volume effect was observed
or both end points. However, whereas the dose–response
elationship for plasma citrulline was significant at Weeks
–5 (Fig. 4), at Weeks 4 and 5 it was significant only for the
oxicity score. Overall, citrullinemia correlates poorly with
he severity of clinical symptoms as graded with the RTOG
cute toxicity score used in this study, although a correlation
as observed with the time that a patient is without symp-
oms (i.e., the % zero score). This may be explained in part
y the fact that radiation-induced epithelial cell loss, which
s typically measured by the plasma citrulline level, is
erely one of several pathophysiological mechanisms un-
erlying clinical symptoms (37–39). Also the fact that the
linical toxicity score, in contrast to plasma citrulline con-
entration, is a subjective score may further contribute to
his poor correlation. The poor correlation between subjec-
ive symptoms, i.e., complaints, and objective end points for
mall-bowel radiation injury has been recognized before
5). Similar drawbacks exist for the use of sophisticated
lanning systems to calculate small-bowel dose and volume
arameters. As reported by others (17, 33), we used a
lanning CT scan for computing a small-bowel DVH. The
BV is reconstructed from the SB contours as delineated on
ach transverse slice, a parameter that will depend highly on
he protocol used for the CT scan, e.g., whether patients are
asted before the scan and if so, for how long? What is the
olume of contrast solution administered, and what is the
ime interval between the contrast administration and the
T scan? A substantial variation exists in the protocols used
y different authors with regard to these aspects (12, 16, 17,
1). Furthermore, without a previous history of abdominal
urgery, the small bowel is a mobile organ. As a conse-
uence, the SBV treated, as well as the dose delivered, to a
articular part of SB will vary daily, not least because of a
ossible variation in bladder filling.
Despite several attempts to standardize registration and
onsequently the publication of treatment-related toxicity,
ost authors still use a toxicity scoring system adjusted to
heir own (historical) clinical practice and/or clinical ques-
ion (42–44), as was also done to some extent in this study.
ecause of this and the fact that toxicity grading systems are
eing adjusted on a regular basis, an objective marker for
ormal-tissue toxicity, such as the plasma creatinine level is
or the kidney function, would definitely be of great benefit.
deally, such a marker should then be easily accessible and
ndependent of medication and metabolic events such as
iet and nutritional status. We did not find a correlation
etween baseline citrulline concentration and body mass
ndex, surgical status, or primary malignancy. Also Crenn et
l. (22) found normal citrulline concentrations in 10 se-
erely malnourished patients with anorexia nervosa.
In contrast to currently used physical parameters (i.e.,
adiation dose and volume parameters), biologic markerssuch as the citrulline concentration) provide information
bout individual biologic variability among patients in
erms of intrinsic radiosensitivity. In the case of acute-
eacting tissues such as the small-intestinal epithelium, such
nformation might prove to be useful as a predictive assay
nd consequently lead to adjustments in the treatment vol-
me and/or total radiation dose.
A rather unexpected finding was the increase of plasma
itrulline concentration during RT in a substantial number
f patients. The analytical method used by us is highly
eproducible (coefficient of variation 3%), excluding a large
ariation in the measured results (35, 45). No dosimetric or
olumetric parameter explained this finding; nor did any of
he patient characteristics such as age or gender (46). A
ingle plasma citrullinemia measurement immediately be-
ore the start of treatment was considered as representative
aseline value in the present study. To the authors’ knowl-
dge, no data exist in the literature about the physiologic
ariation of plasma citrulline concentration in time. How-
ver, the mean  SEM baseline value in the present study
30.9  2.1 M) is in complete agreement with previous
ndings at our laboratory in healthy volunteers under sim-
lar conditions of starvation (47). Interestingly, the mode of
urgical treatment was different in patients who dis-
layed an increased plasma citrulline concentration. Thus
rise in plasma citrulline was observed during RT in 5 of
patients (83%) who underwent extraperitoneal surgery
efore RT as compared to 0 of 17 patients with different
odes of surgical intervention. An explanation for this
an be only speculative. Although all patients had normal
enal function before the start of RT, a temporary decline
f renal function cannot be ruled out. A reactive prolif-
ration of SB epithelium might be another possibility that
ould be in agreement with data so far published on
itrulline as a marker for functional enterocytes (21–26,
6) and the observation that plasma citrulline concentra-
ion may change rapidly in response to altered pathophys-
ological conditions (24).
In summary, small bowel is an important dose-limiting
ormal tissue during treatment of abdominal or pelvic
ancers with radiotherapy. Furthermore, combined radio-
herapy with chemotherapy is being used more frequently
or an increasing number of malignancies originating at
bdominal or pelvic sites (48 –50). Because many of the
rugs used affect also the proliferative activity at the
rypts, treatment-related bowel toxicity will be enhanced
48). Epithelial cell loss has been associated with radia-
ion-induced changes in small-bowel function (9, 18 –20).
ainly for practical reasons, currently available tests for
B radiation damage are not suitable for monitoring
urposes during and after fractionated radiation (38). We
hose citrullinemia for its methodological simplicity (21–
6, 36) and the lack of methodological drawbacks, as
entioned before. As a whole, plasma citrulline seems to
e a quantitative parameter independent of the underlying
ause for epithelial cell loss (21–23). Consequently, this
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orbidity. The present study provides the proof of prin-


















urgery (21), celiac and nonceliac disease (22), and post-
ransplantation cellular rejection (23, 24)—as an assay
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